US FDA Ends Nearly 2-Year Drought In Biosimilar Action Package Postings
Posting of final review documents for three biosimilars – Cyltezo, Mvasi and Fulphila – brings to seven the number of licensed biosimilars for which action packages with underlying analytical and clinical data are publicly available. FDA has attributed posting delays to a backlog in the redaction queue but is not prioritizing postings based upon order of approval or commercial availability.
You may also be interested in...
Chronicle of the development and US FDA review of Mylan’s pegfilgrastim-jmdb (MYL-1401H), a biosimilar to Amgen’s Neulasta.
FDA staff who participated in the review of Mylan’s pegfilrastim-jmdb, the first US-licensed biosimilar to Amgen’s Neulasta.